HDAC inhibitors: Double edge sword for TRAIL cancer therapy?

Cancer Biology and Therapy

Volumn 4, Issue 10, 2005, Pages 1113-1115

  Fulda, Simone ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Cancer; HDAC inhibitors; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; OXAMFLATIN; THIOREDOXIN; TRICHOSTATIN A;

CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER THERAPY; CHROMATIN; CLINICAL TRIAL; HUMAN; NOTE; TUMOR GROWTH;

EID: 27744591014     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.10.2100     Document Type: Note

References (24)

1. Fulda S, Debatin KM. Exploiting death, receptor signaling pathways for tumor therapy. Biochim Biophys Acta (BBA) - Rev Cancer 2004; 1705:27-41.
2. LeBlanc HN, Ashkenazi A. Apo-2L/TRAIL and its death and decoy resceptors. Cell Death Differ 2003; 10:66-75.
3. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80.
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202.
5. Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/Tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64:2580-9.
6. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2:1273-84.
7. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11:S193-206.
8. Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004; 314:186-91.
9. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DBJ, Dyer MJS, Cohen GM. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12:773-82.
10. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24:4609-23.
11. Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004; 25:1813-20.
12. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004; 23:6261-71.
13. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1. Exp Cell Res 2004; 298:560-73.
14. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck, JF. Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs 2005; 23:99-109.
15. Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH, Evers BM. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001; 130:265-72.
16. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003; 66:1537-45.
17. VanOosten RL, Moore JM, Ludwig AT, Griffith TS. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid Rafts. Mol Ther 2005; 11:542-52.
18. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticacner agents. Ann Rev Pharm Toxicol 2005; 45:495-528.
19. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23:6693-701.
20. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. PNAS 2005; 102:673-8.
21. Yoshida T, Sakai T. In: Litwack G, ed. Vitamins and Hormones. Academic Press, 2004:35-49.
22. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19:1735-43.
23. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ, Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3:409-16.
24. Higuchi H, Grambihler A, Canbay A, Bronk SF, Gores GJ. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 2004; 279:51-60.